论文部分内容阅读
本文复习了114例己充分追踪达五年以上,曾施行经尿道切除治愈或控制的膀胱肿瘤病人,这些病人曾有一次或数次复发。肿瘤复发为较高级的占19％,较高期的占22％。从原发肿瘤的治疗到复发为较高级或较高期的间隔期为三个月至27年。当一个低级或低期的肿瘤在不足三年期间复发为一个较高的级或期的肿瘤时,应作更积极的治疗。 Hugh J.Jewett医生(博士)对泌尿专科有许许多多的杰出贡献,他不仅是泌尿学杂志的主编。全世界的泌尿科医生应该感谢他为我们的专科的利益不倦地努力的恩义。他的贡献增加我们对膀胱肿瘤的诊断,鉴别诊断和治疗的知识,激励我们在泌尿学领域中从事临床研究。经尿道切除的膀胱肿瘤复发率大约为60％。有些复发病例病情恶化并终归因赘瘤而致病人死亡,而有一些复发后的病例与原发肿瘤同级同期,尚有一些为较高或较低级或期。这些临床随访研究是试图确定那些肿瘤将不复发,那些将复发为同级同期和将复发为更高级更高期,或造成死亡。
This article reviewed 114 patients with bladder tumors who had been fully tracked for more than five years and who had been cured or controlled by transurethral resection. These patients had had one or more relapses. Tumor recurrence accounted for 19% of higher grades and 22% of higher grades. The interval from the treatment of primary tumors to recurrences to higher or higher stages ranges from three months to 27 years. When a low-grade or low-grade tumor relapses into a higher grade or stage tumor in less than three years, more aggressive treatment should be performed. Dr. Hugh J. Jewett (Ph.D.) has many outstanding contributions to urology, he is not only the chief editor of the Journal of Urology. Urologists all over the world should thank him for the tireless efforts of our specialties. His contributions have increased our knowledge in the diagnosis of bladder tumors, differential diagnosis and treatment, and have encouraged us to conduct clinical research in the field of urology. The recurrence rate of transurethral resection of bladder tumors is approximately 60%. Some of the relapsed cases deteriorated and were eventually attributed to tumors that caused the death of the patients. Some cases of recurrence were at the same stage as the primary tumors, and some were higher or lower. These clinical follow-up studies are trying to determine which tumors will not relapse, those that will relapse into the same stage and will relapse into higher advanced stages, or cause death.